STUDY PROTOCOL

Study protocol: The clinical features, epidemiology, and causes of paediatric encephalitis in southern Vietnam [version 1; peer review: 1 approved]

Nguyen Hoang Thien Huong ^{1,2}, Nguyen Duc Toan ², Du Tuan Quy²,
Truong Huu Khanh², Le Quoc Thinh², Le Nguyen Thanh Nhan^{1,2},
Ngo Ngoc Quang Minh², Hugo Turner ², Louise Thwaites ², Sarosh Irani ³,
Nguyen Thanh Hung¹, Le Van Tan ¹

¹Oxford University Clinical Research Unit, Ho Chi Minh City, 700000, Vietnam

²Children's Hospital 1, Ho Chi Minh City, 700000, Vietnam

³Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

V1 First published: 28 May 2021, 6:133
<https://doi.org/10.12688/wellcomeopenres.16770.1>
 Second version: 30 Jun 2021, 6:133
<https://doi.org/10.12688/wellcomeopenres.16770.2>
 Latest published: 13 Sep 2022, 6:133
<https://doi.org/10.12688/wellcomeopenres.16770.3>

Abstract

Encephalitis is a major cause of morbidity and mortality worldwide. The clinical syndrome of encephalitis consists of altered mental status, seizures, neurologic signs, and is often accompanied by fever, headache, nausea, and vomiting. The encephalitis in children has been known that more common than in adult, with the incidence rate of infants was 3.9 times higher than that of people 20-44 years of age. The reported incidence of hospitalization attributed to paediatric encephalitis ranged from 3 to 13 admissions per 100,000 children per year with the overall mortality ranging from 0 to 7%. There are however more than 100 pathogens that can cause encephalitis and accurate diagnosis is challenging. Over 50% of patients with encephalitis are left undiagnosed despite extensive laboratory investigations. Furthermore, recent studies in high-income settings have suggested autoimmune encephalitis has now surpassed infectious aetiologies, mainly due to increased awareness and diagnostic capacity, which further challenges routine diagnosis and clinical management, especially in developing countries. There are limited contemporary data on the causes of encephalitis in children in Vietnam. Improving our knowledge of the causative agents of encephalitis in this resource-constrained setting remains critical to informing case management, resource distribution and vaccination strategy. Therefore, we conduct a prospective observational study to characterise the clinical, microbiological, and epidemiological features of encephalitis in a major children's hospital in southern Vietnam.

Open Peer Review

Approval Status

	1	2
version 3		
(revision)		
13 Sep 2022		view
version 2		
(revision)		
30 Jun 2021		view
version 1		
28 May 2021	view	

1. **Elizabeth M. Molyneux** , University of Malawi, Blantyre, Malawi
2. **Emma C. Thomson** , University of Glasgow, Glasgow, UK

Any reports and responses or comments on the article can be found at the end of the article.

Admission clinical samples will be collected alongside meta clinical data and from each study participants. A combination of classical assays (serology and PCR) and metagenomic next-generation sequencing will be used to identify the causative agents. Undiagnosed patients with clinical presentations compatible with autoimmune encephalitis will then be tested for common forms of the disease. Finally, using direct- and indirect costs, we will estimate the economic burden of hospitalization and seven days post hospital discharge of paediatric encephalitis in our setting.

Keywords

encephalitis, next-generation sequencing, pathogens, autoimmune, anti-NMDAR

This article is included in the [Oxford University Clinical Research Unit \(OUCRU\)](#) gateway.

Corresponding authors: Nguyen Hoang Thien Huong (huongnht@oucrU.org), Le Van Tan (tanlv@oucrU.org)

Author roles: **Huong NHT:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Methodology, Project Administration, Resources, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Toan ND:** Writing – Review & Editing; **Quy DT:** Project Administration, Writing – Review & Editing; **Khanh TH:** Project Administration, Writing – Review & Editing; **Thinh LQ:** Resources, Writing – Review & Editing; **Nhan LNT:** Project Administration; **Minh NNQ:** Project Administration; **Turner H:** Writing – Original Draft Preparation; **Thwaites L:** Writing – Original Draft Preparation, Writing – Review & Editing; **Irani S:** Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Hung NT:** Supervision; **Tan LV:** Conceptualization, Funding Acquisition, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust [106680, to the Oxford University Clinical Research Unit in Vietnam; 204904, to L.V.T.] and the Bill and Melinda Gates Foundation [OPP1211860].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Huong NHT *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Huong NHT, Toan ND, Quy DT *et al.* **Study protocol: The clinical features, epidemiology, and causes of paediatric encephalitis in southern Vietnam [version 1; peer review: 1 approved]** Wellcome Open Research 2021, 6:133 <https://doi.org/10.12688/wellcomeopenres.16770.1>

First published: 28 May 2021, 6:133 <https://doi.org/10.12688/wellcomeopenres.16770.1>

Introduction

Encephalitis is an inflammation of the brain parenchyma and is associated with neurologic dysfunction. The clinical features include (but are not limited to) altered mental status (decreased level of consciousness, lethargy, personality change, unusual behaviour), seizures, and/or focal neurologic signs, which are often accompanied by fever, headache, nausea, and vomiting¹. Encephalitis is a significant cause of morbidity and mortality worldwide², especially in the paediatric population³. In a study of 7000 children admitted to hospital with suspected encephalitis in the United States between 2004 and 2013, 40% of children required admission to the paediatric intensive care unit, with a median length of hospital stay of 16 days⁴. The overall mortality of childhood encephalitis ranges from 0 to 7%^{5,6}. However, neurological deficits are recorded in the majority of the patients at hospital discharge. Persistent neurologic consequences may include personality change, behaviour disorder (including attention deficit disorder), movement disorder (including tic disorders), intellectual disability, learning disorders, blindness, paresis, ataxia, recurrent headaches, and sleeping problems^{7,8}.

Clinical outcomes of encephalitis are highly dependent on the identification of the causative agents and timely initiation of appropriate clinical management approaches. Current diagnostics are inadequate and globally the causative agents are only identified in <50% of patients⁹. In the California Encephalitis Project, 1570 patients who were at least six months of age (median age 23 years) were enrolled in the study between 1998 and 2005, and despite extensive microbiologic investigations, no aetiology was identified in 63% of cases¹⁰. Of the patients with an aetiology identified, a confirmed or probable infectious aetiology was identified in 16%, with viruses (enteroviruses and herpes simplex virus) being the most common causes, accounting for 69% of the detected pathogens. The most commonly identified pathogenic viruses were enteroviruses (for 25% of cases) and herpes simplex virus-1 (for 24% of cases)¹¹. Results from studies conducted elsewhere in western countries showed that a confirmed or probable infectious aetiology was identified in approximately 40% – 60% of cases, and a possible cause was identified in approximately 25%^{6,12,13}. In southern Vietnam, there has been only one comprehensive study on paediatric encephalitis conducted from 2003 – 2004. Of 194 enrolled children presenting with encephalitis, a viral agent was established in 41%. The most common pathogen was Japanese encephalitis virus (n=50, 26%), followed by enteroviruses (n=18, 9.3%), dengue virus (n=9, 4.6%), herpes simplex virus (n=1), cytomegalovirus (n=1) and influenza A virus (n=1). An unfavourable outcome was recorded in 54% of the patients, including 57 (29%) fatal cases¹¹.

In addition, Vietnam and Asia are highly susceptible to emerging infectious diseases, including those caused by novel neurotropic pathogens (e.g., Nipah virus, enterovirus A71, and SARS-CoV-2). New diagnostic approaches are thus urgently required for the rapid response to these evolving challenges and to improve clinical outcomes.

The emergence of new pathogens causing encephalitis, the wide spectrum of known viruses responsible, the low sensitivity of current diagnostic methods and the high mortality and morbidity associated with encephalitis make it an attractive candidate for novel diagnostic assays such as metagenomic next-generation sequencing (mNGS). mNGS allows for nucleic acids to be directly sequenced from clinical samples without the requirement of prior knowledge of the targeted pathogens. As such, a mNGS-based diagnostic approach has the potential to revolutionize the study of genomics and the diagnosis of infectious diseases.

Anti-NMDAR encephalitis was first discovered in 2007 as a phenomenon associated with underlying ovarian teratoma. Over the last years, its epidemiology has shifted substantially; it has more often been reported in female patients without tumour, males and children. Anti-NMDAR has since become one of the most common forms of encephalitis, especially in children, worldwide^{14–19}. In Vietnam we have recently described the diagnosis, clinical management, and long-term outcome of the first case series of anti-NMDAR encephalitis admitted to the Hospital for Tropical Disease (HTD) between 2015 and 2016²⁰. At Children's Hospital 1 in Ho Chi Minh City, Vietnam, anti-NMDAR encephalitis has recently been diagnosed in 4/6 cases.

This study aims to improve our knowledge about the causes of paediatric encephalitis in southern Vietnam. Specifically, our aims are to describe the epidemiology, clinical profiles, in-hospital outcome and causes of encephalitis in children in southern Vietnam; to assess the utility potential of mNGS in terms of detecting a broad range of known/unknown pathogens in clinical samples, especially cerebrospinal fluid; and to estimate the economic burden attributed to paediatric encephalitis in southern Vietnam.

Objectives

- To determine the epidemiology, clinical characteristics and hospital outcomes of paediatric encephalitis in southern Vietnam.
- To identify the frequency of infectious aetiologies and autoimmune causes detected in clinical samples, especially cerebrospinal fluid, of paediatric patients presenting with encephalitis allied with clinical outcome.
- To assess the utility potential of mNGS in the diagnosis of paediatric encephalitis in Vietnam.
- To estimate the economic burden attributed to encephalitis in children.

Methods

Study design and setting

The study will be prospectively conducted at Children's Hospital 1 in Ho Chi Minh City in Vietnam between 2020 and 2022. Children's Hospital 1 is a 1,600-bed hospital, and is the largest tertiary hospital for children coming from southern provinces of Vietnam with a catchment population of over

40 million. Annually, Children's Hospital 1 has approximately 90,000 admissions. Of these, 150–200 cases presented with encephalitis, with infants and neonates accounting for ~35%¹¹.

Participants

Inclusion criteria. Any children admitted to the Department of Infectious Diseases and Neurology of Children's Hospital 1 and fulfilling the case definition of encephalitis will be eligible to be invited to participate in the study.

Exclusion criteria. Patients will be excluded if no informed consent was obtained.

Case definition

Encephalitis in children¹ will be diagnosed when the patient has altered mental status (i.e., decreased or altered level of consciousness, lethargy, or personality change) lasting ≥ 24 hours with no alternative cause identified and ≥ 2 of these following criteria for a “possible” diagnosis or ≥ 3 of these following criteria for a “probable” diagnosis: documented fever $\geq 38^\circ\text{C}$ (100.4°F) within 72 hours (before or after) presentation, generalized or partial seizures not fully attributable to pre-existing seizure disorder, new onset focal neurologic findings, cerebral spinal fluid white blood cell count ≥ 5 cells/mm³, abnormality of brain parenchyma on neuroimaging suggestive of encephalitis that is new or appears to have acute onset, and abnormality on electroencephalogram that is consistent with encephalitis and not attributable to any other causes¹.

Sample size

Given the descriptive nature of the present study, sample size calculation was not sought. We aim to carry out patient recruitment from 2020 to 2022. Based on our admission data, we anticipate that 100–150 patients will be enrolled every year.

Data collection

Clinical data including dates of birth, admission and discharge, demographic data (date of birth, gender, place of residence, date admitted/discharged to/from the hospital), clinical signs, symptoms and syndromes, routine laboratory and imaging results (cerebrospinal fluid (CSF), urine and plasma samples, electroencephalogram (EEG), magnetic resonance imaging (MRI), computed tomography (CT) scan, diagnosis and differential diagnosis, associated diseases and co-morbidity, and treatment (immunotherapy with methylprednisolone, intravenous immunoglobulin, haloperidol, antiepileptic medications, tumour removal, plasmapheresis, etc.) will be collected.

Glasgow coma scale (GCS) and modified Rankin Scale (mRS) for children will be used to measure the hospital outcomes of patients in this study. The mRS was previously used in a UK-based surveillance study of encephalitis in children, and in another study using data from Evelina Children's Hospital, Great Ormond Street Children's Hospital, St George's Hospital, King's College Hospital in London and Birmingham Children's Hospital in Birmingham between 2007 and 2010^{17,21}.

We will also collect data on indirect- and direct- costs of illness from each study participant²². Direct costs include costs attributable to medical health care and treatment during hospitalization. Indirect costs are costs incurred by parents or relatives who take care of the patients during hospitalization and seven days after discharge.

For laboratory analysis, we will collect a wide range of admission clinical samples including CSF, urine, plasma, rectal and throat swabs.

Laboratory procedures

Routine diagnostics. As part of routine care at Children's Hospital 1, CSF specimens of patients presenting with brain infections are subject to cultured and/or examined by microscopy for detection of bacterial/fungal/*Mycobacterium tuberculosis* infection with the use of standard methods when appropriate. Patients with encephalitis are further tested for herpes simplex virus and Japanese encephalitis virus using PCR and serology, respectively. Additional testing will include common causes of encephalitis such as enterovirus and varicella zoster virus, which will be carried out on archived CSF samples as part of the investigation of the present clinical study.

Next-generation sequencing. Regardless of the results of investigation using classical assays outlined above, collected clinical samples (CSF, urine, plasma, and rectal and throat swabs) will be analysed using our in-house metagenomic next-generation sequencing (mNGS) workflow^{23–25}. Biological samples will be sequenced and the obtained results will be compared against that of current (routine) diagnostic assays (especially PCRs). The aim is also to explore the utility of CSF and non-CSF samples for the diagnosis of encephalitis using mNGS. When appropriate, mNGS results obtained during the study period will be reported back to the treating physician only for their reference. This mNGS is currently not a standard diagnostic assay for encephalitis.

Immunological assays. Undiagnosed patients with clinical presentations compatible with autoimmune encephalitis will then be tested for possible forms of the disease using EUROIMMUN assay (NMDAR)²⁶ and in-house assays (AMPA, GABA and VGKC-associated proteins)²⁷, which have been developed by Dr Irani and his group in Oxford. More specifically, the study involves exporting cerebral spinal fluid to Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom (Dr Sarosh Irani's laboratory) and storage there for the purpose of immunological assays mentioned above.

Data management

All available data will be entered into an electronic database (CliRes) developed by the IT department of the Oxford University Clinical Research Unit. Only the named investigators or their designee(s) will have access to this information. All other investigators will be regularly updated and will be granted access to data when requested. Patients will not be

identified by their names. The investigators are responsible for maintaining all study records. The investigators are responsible for the timeliness, completeness and accuracy of the information in the original dataset and the clinical data management system. Laboratory staff will record specimens, their aliquots, and their storage location. All necessary tools, instruction, and training will be provided to all site staff involved in data entry to ensure the correct and consistent completion database prior to the study starting.

Data storage

The investigators are responsible for retaining all essential data for at least five years after the completion of the study. Original paper documents will be maintained for a minimum of five years and electronic documents retained thereafter. All stored records are to be kept secure and confidential.

Quality control procedures

The study will be conducted in compliance with the current approved protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), relevant regulations and standard operating procedures. Regular monitoring will be performed according to ICH GCP. Data, samples and procedures will be evaluated for compliance with the protocol, standard operating procedures, regulatory requirements and terms of ethical approval. Records will be verified for accuracy against source documents and physical inventory of samples. The diagnostic laboratory at Children's Hospital 1 conducts regular internal and external quality control procedures.

Data analysis

Descriptive statistics will be employed to compare the epidemiology, clinical presentation, laboratory findings, patient treatment, and outcomes of patients. Data will be presented in the form of tables and charts for descriptive variables. When relevant, sophisticated statistical modelling approaches will be utilized to identify prognostic factors for (long-term) clinical outcomes. Association between pathogenic profile and outcomes of patients will be determined by univariable and multivariable analysis using logistic regression. All statistical analysis will be performed using Stata version 14 (StataCorp LP, College Station, TX, USA) and R; and p-values of ≤ 0.05 will be considered significant. We will estimate direct and indirect costs attributed to encephalitis using data collected from patients enrolled into the clinical studies.

Consent

Written informed consent will be obtained from all study participants or their representatives before any data from patients is collected for the study. The study staff will discuss the study with the parent/representative of potential participants. Study staff will describe the purpose of the study, the study procedures, possible risks/benefits, the rights and responsibilities of patient, and alternatives to enrolment. The parent/representative will be invited to ask questions which will be answered by study staff, and they will be provided with appropriate numbers to contact if they have any questions subsequently. If

the parent/representative agrees for their child to participate, they will be asked to sign and date two copies of an informed consent form²⁸. A copy of the form will be given to them to keep. If required, the parent/representative will be given up to 48 hours to consider for their children to take part in the study. In addition to the procedures above, illiterate signatories will have the informed consent form read to them in the presence of a witness who will sign to confirm that the form was read accurately and that the participant or representative agrees to participation. All informed consent forms will be written in the local language and will use terms that are easily understandable.

Ethics

This protocol and the relevant supporting documents have been approved by the ethical committee of Children's Hospital 1 (1503/QD-BVND1) and the Oxford Tropical Research Ethics Committee (OxTREC 7-20)²⁸. The collection of all biological samples is performed as part of routine clinical assessments and are consistent with the local standard of care and good clinical practice.

Dissemination and data sharing

The contributions of investigators from collaborating sites (Children's Hospital 1, the Oxford University Clinical Research Unit, and the University of Oxford) will be recognized in authorship allocation in accordance with the guidelines of the International Committee of Medical Journal Editors. Data from this study is of substantial interest to the scientific and clinical research communities. Manuscripts arising from this study will, wherever possible, be submitted to peer-reviewed journals. All publications will acknowledge the study's funding sources. Data exchange complies with Information Governance and Data Security Policies in all of the relevant countries.

Study status

At the time of protocol submission, all participating sites had been identified and recruitment had started.

Discussion

The strength of our study is that it will contribute to the knowledge of scientists and clinicians in a low- and middle-income setting as currently, very little is known about the causative agents and the autoimmune features of encephalitis in children in Vietnam. Consequently, the clinical, microbiological, and genomic data produced by this study will be essential information for clinical practice and the development of future guidelines. This study will be conducted at the largest tertiary paediatric hospital in southern Vietnam. In this study, we will integrate the clinical assessments with microbiology, detailed genomics data, and immunological studies to further characterize the features of encephalitis in our setting.

Our study has several limitations. Firstly, ethical issues will complicate the way we conduct research in severely ill children with encephalitis, because children who are older than

12 years-old need to agree to join the study and sign a separate informed consent form on their own, which they cannot complete if the condition of their disease is severe. Secondly, there are no systematic guidelines ensuring accurate management of encephalitis (especially autoimmune encephalitis) at Children's Hospital 1. Finally, data collection at a single paediatric hospital may limit the applicability of the results to other places in Vietnam.

Encephalitis is an obvious cause of morbidity and mortality of children in low- and middle-income countries including Vietnam. Generally, the main issues of encephalitis in children are the requirement for state-of-the-art laboratory tools for better and early diagnosis and the need for effective treatment. If this study shows that the metagenomics approach is useful, future research should focus on validity and applicability of proteomics-based experiments, molecular techniques or better markers of inflammation in order to develop rapid diagnostic tests for early detection of encephalitis, its pathogenic organisms, and methods to treat this condition effectively. With highly sensitive and specific diagnostic tools, the treatment of encephalitis in children would be significantly changed so that medical therapy could be safely and comprehensively administered or withheld. All of these factors

may lead to costs reduction and the improvement of overall outcomes of paediatric encephalitis.

Data availability

Underlying data

No data are associated with this article.

Extended data

Zenodo: Study protocol: The clinical features, epidemiology, and causes of pediatric encephalitis in southern_ICF_OxTREC APPROVAL. <https://doi.org/10.5281/zenodo.4780771>²⁸.

This project contains the following extended data:

- INFORMED CONSENT FORM_Paediatric Encephalitis in Vietnam (01).docx
- INFORMED CONSENT FORM_Paediatric Encephalitis in Vietnam (02).docx
- OxTREC APPROVAL_Paediatric Encephalitis in Vietnam.pdf

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

References

1. Venkatesan A, Tunkel AR, Bloch KC, *et al.*: **Case Definitions, Diagnostic Algorithms, and Priorities in Encephalitis: Consensus Statement of the International Encephalitis Consortium.** *Clin Infect Dis.* 2013; **57**(8): 1114–28. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Boucher A, Herrmann JL, Morand P, *et al.*: **Epidemiology of infectious encephalitis causes in 2016.** *Med Mal Infect.* 2017; **47**(3): 221–235. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Parpia AS, Li Y, Chen C, *et al.*: **Encephalitis, Ontario, Canada, 2002–2013.** *Emerg Infect Dis.* 2016; **22**(3): 426–32. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Bagdure D, Custer JW, Rao S, *et al.*: **Hospitalized Children With Encephalitis in the United States: A Pediatric Health Information System Database Study.** *Pediatr Neurol.* 2016; **61**: 58–62. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Rautonen J, Koskinen M, Vaheri A: **Prognostic factors in childhood acute encephalitis.** *Pediatr Infect Dis J.* 1991; **10**(6): 441–6. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Fowler A, Stöberg T, Eriksson M, *et al.*: **Childhood encephalitis in Sweden: Etiology, clinical presentation and outcome.** *Eur J Paediatr Neurol.* 2008; **12**(6): 484–90. [PubMed Abstract](#) | [Publisher Full Text](#)
7. Fowler A, Stöberg T, Eriksson M, *et al.*: **Long-term Outcomes of Acute Encephalitis in Childhood.** *Pediatrics.* 2010; **126**(4): e828–35. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Michaeli O, Kassir I, Shachor-Meyouhas Y, *et al.*: **Long-term Motor and Cognitive Outcome of Acute Encephalitis.** *Pediatrics.* 2014; **133**(3): e546–52. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Granerod J, Tam CC, Crowcroft NS, *et al.*: **Challenge of the unknown. A systematic review of acute encephalitis in non-outbreak situations.** *Neurology.* 2010; **75**(10): 924–32. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Glaser CA, Honarmand S, Anderson LJ, *et al.*: **Beyond Viruses: Clinical Profiles and Etiologies Associated with Encephalitis.** *Clin Infect Dis.* 2006; **43**(12): 1565–77. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Le VT, Phan TQ, Do QH, *et al.*: **Viral etiology of encephalitis in children in southern Vietnam: results of a one-year prospective descriptive study.** Singh SK, editor. *PLoS Negl Trop Dis.* 2010; **4**(10): e854. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Galanakis E, Tzoufi M, Katragkou A, *et al.*: **A prospective multicenter study of childhood encephalitis in Greece.** *Pediatr Infect Dis J.* 2009; **28**(8): 740–2. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Kolski H, Ford-Jones EL, Richardson S, *et al.*: **Etiology of Acute Childhood Encephalitis at The Hospital for Sick Children, Toronto, 1994–1995.** *Clin Infect Dis.* 1998; **26**(2): 398–409. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Armangue T, Titulaer MJ, Málaga I, *et al.*: **Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients.** *J Pediatr.* 2013; **162**(4): 850–856.e2. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Florance-Ryan N, Dalmau J: **Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents.** *Curr Opin Pediatr.* 2010; **22**(6): 739–44. [PubMed Abstract](#) | [Publisher Full Text](#)
16. Gable MS, Sheriff H, Dalmau J, *et al.*: **The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project.** *Clin Infect Dis.* 2012; **54**(7): 899–904. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Wright S, Hachon Y, Jacobson L, *et al.*: **N-methyl-D-aspartate receptor antibody-mediated neurological disease: Results of a UK-based surveillance study in children.** *Arch Dis Child.* 2015; **100**(6): 521–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Goldberg EM, Titulaer M, de Blank PM, *et al.*: **Anti-N-methyl-D-aspartate Receptor-Mediated Encephalitis in Infants and Toddlers: Case Report and Review of the Literature.** *Pediatr Neurol.* 2014; **50**(2): 181–4. [PubMed Abstract](#) | [Publisher Full Text](#)
19. Ryan N: **Anti-N-Methyl-d-Aspartate Receptor-Mediated Encephalitis: Recent Advances in Diagnosis and Treatment in Children.** *Curr Probl Pediatr Adolesc Health Care.* 2016; **46**(2): 58–61. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Nguyen Thi Hoang M, Nguyen Hoan P, Le Van T, *et al.*: **First reported cases of**

- anti-NMDA receptor encephalitis in Vietnamese adolescents and adults.** *J Neurol Sci.* 2017; **373**: 250–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Hachohen Y, Wright S, Waters P, *et al.*: **Paediatric autoimmune encephalopathies: Clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens.** *J Neurol Neurosurg Psychiatry.* 2013; **84**(7): 748–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Nhan LNT, Turner HC, Khanh TH, *et al.*: **Economic Burden Attributed to Children Presenting to Hospitals With Hand, Foot, and Mouth Disease in Vietnam.** *Open Forum Infect Dis.* 2019; **6**(7): ofz284.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 23. Anh NT, Hong NTT, Nhu LNT, *et al.*: **Viruses in Vietnamese Patients Presenting with Community-Acquired Sepsis of Unknown Cause.** Tang Y-W, editor. *J Clin Microbiol.* 2019; **57**(9): e00386–19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 24. Anh NT, Nhu LNT, Thu Hong NT, *et al.*: **Viral metagenomic analysis of cerebrospinal fluid from patients with acute central nervous system infections of unknown origin, Vietnam.** *Emerg Infect Dis.* 2021; **27**(1): 205–213.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Hong NTT, Anh NT, Mai NTH, *et al.*: **Performance of Metagenomic Next-Generation Sequencing for the Diagnosis of Viral Meningoencephalitis in a Resource-Limited Setting.** *Open Forum Infect Dis.* 2020; **7**(3): ofaa046.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Suh-Lailam BB, Haven TR, Copple SS, *et al.*: **Anti-NMDA-receptor antibody encephalitis: performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay.** *Clin Chim Acta.* 2013; **421**: 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Reyes NGD, Prado MB, Turalde CWR, *et al.*: **Autoimmune encephalitis associated with two antibodies.** *Epilepsy Behav Case Rep.* 2018; **10**: 44–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 28. Huong NHT, Toan ND, Quy DT, *et al.*: **Study protocol: The clinical features, epidemiology, and causes of pediatric encephalitis in southern Vietnam.** ICF_OxTREC APPROVAL. 2021.
<http://www.doi.org/10.5281/zenodo.4780771>

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 07 June 2021

<https://doi.org/10.21956/wellcomeopenres.18495.r44137>

© 2021 Molyneux E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Elizabeth M. Molyneux

Department of Paediatrics, University of Malawi, Blantyre, Malawi

Neurological infections cause significant long-term morbidity and a high mortality rate. In children, most of the research, especially in LMICs has focussed on bacterial infections. This is because the tools for diagnosing common bacterial agents are widely available and treatment is known. These studies have fuelled the development and rollout of antibacterial vaccines with a large drop in paediatric cases: the picture is less rosy in neonates.

With the reduction in bacterial neurological infections, the proportion of viral cases has increased. New diagnostics have made it simpler to identify the cause and the increase in antiviral medications has improved outcome. Now new diagnostic tools, such as metagenomic next generation sequencing (mNGS) have entered the field that allow a wider net to be cast in trying to identify the aetiological agents. Also there is new and heightened interest in autoimmune causes of encephalitis which are probably responsible for a significant number of the present day undiagnosed causes of encephalitis.

In Vietnam, an aetiological study of encephalitis was carried out in 2003-2004, and 41% were of viral cause, Japanese encephalitis (26%) enteroviruses (9.3 %) and dengue (4.6%) being the most common; 54% did badly of whom 29% died. Since then different, sometimes novel viruses have been identified as causing encephalitis.

In this descriptive study, the investigators plan to collect detailed clinical, laboratory, imaging and outcome data on children admitted to one large Vietnamese children's hospital in 2021-2022. They anticipate that 100-150 children will be enrolled. A wide range of clinical samples will be taken on admission on which microscopy and culture will be undertaken in real time according to the hospital routine standard of care, for bacteria, fungi and TB, and if appropriate, serology and PCR for Japanese encephalitis and herpes simplex viruses. Stored samples will be tested for varicella zoster virus and enteroviruses. All CSF, plasma, throat, urine and stool samples will undergo mNGS regardless of the results from other diagnostic tests. On the samples in which no causative agent has been identified immunological assays will be done in Oxford using EUROIMMUN assay (NMDAR) and in-house assays (AMPA, GABA and VGKC-associated proteins).

I only have one or two questions to ask, namely;

- What age range of children is to be enrolled and will results be analysed by age?
- What does the routine immunisation programme for children include and at what ages? I assume this data will be collected.
- Will nutritional status be recorded?
- The study is to be undertaken at a large tertiary hospital. How do children get admitted to the hospital? Are most of them referred from other health facilities or do most self-refer?
- How long have children been unwell before being admitted and what previous treatment are they likely to have received? (All of which I presume will be collected) Will this affect any of the anticipated diagnostic tests.

The investigators are to be congratulated for proposing a careful, all-round descriptive study of an important topic with the real and practical possibility of improving diagnosis, treatment and outcome for children with encephalitis.

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: My research has been in paediatric bacterial meningitis and into managing convulsions in a low income country.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.